Adaptive Biotechnologies Corporation2024财年第一财季实现净利润-47.51百万美元，同比增加17.66%

自选股智能写手05-13

3月31日，Adaptive Biotechnologies Corporation（ADPT.US）公布财报，公告显示公司2024财年第一财季净利润为-47.51百万美元，同比增加17.66%；其中营业收入为41.87百万美元，同比增加11.21%，每股基本收益为-0.33美元。从资产负债表来看，Adaptive Biotechnologies Corporation（ADPT.US）总负债...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2435359591?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2024-05-13 00:22","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2435359591","market":"us","top_or_hot":-1,"title":"Adaptive Biotechnologies Corporation2024财年第一财季实现净利润-47.51百万美元，同比增加17.66%","media":"自选股智能写手","content":"<div>\n<p>3月31日，Adaptive Biotechnologies Corporation（ADPT.US）公布财报，公告显示公司2024财年第一财季净利润为-47.51百万美元，同比增加17.66%；其中营业收入为41.87百万美元，同比增加11.21%，每股基本收益为-0.33美元。从资产负债表来看，Adaptive Biotechnologies Corporation（ADPT.US）总负债...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240513002220875f0a1f&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Adaptive Biotechnologies Corporation2024财年第一财季实现净利润-47.51百万美元，同比增加17.66%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAdaptive Biotechnologies Corporation2024财年第一财季实现净利润-47.51百万美元，同比增加17.66%\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-05-13 00:22 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240513002220875f0a1f&s=b><strong>自选股智能写手</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>3月31日，Adaptive Biotechnologies Corporation（ADPT.US）公布财报，公告显示公司2024财年第一财季净利润为-47.51百万美元，同比增加17.66%；其中营业收入为41.87百万美元，同比增加11.21%，每股基本收益为-0.33美元。从资产负债表来看，Adaptive Biotechnologies Corporation（ADPT.US）总负债...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240513002220875f0a1f&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ADPT","symbol_name":"Adaptive Biotechnologies Corp","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240513002220875f0a1f&s=b","article_id":"2435359591","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240513002220875f0a1f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2435359591","pubTimestamp":1715530934,"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"3月31日，Adaptive Biotechnologies Corporation公布财报，公告显示公司2024财年第一财季净利润为-47.51百万美元，同比增加17.66%；其中营业收入为41.87百万美元，同比增加11.21%，每股基本收益为-0.33美元。从资产负债表来看，Adaptive Biotechnologies Corporation总负债3.46亿美元，其中短期债务9.59百万美元，资产负债比为1.80，流动比率为0.05。机构评级：截至2024年3月31日，当前有6家机构对Adaptive Biotechnologies Corporation目标价做出预测，其中目标均价为6.33美元，其中最低目标价为5.00美元，最高目标价为10.00美元。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":["earning"],"viewcount":null,"language":"zh","relate_stocks":{"ADPT":"Adaptive Biotechnologies Corp"},"translate_title":"Adaptive Biotechnologies Corporation achieved a net profit of-US $47.51 million in the first quarter of fiscal year 2024, a year-on-year increase of 17.66%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ADPT":1},"content_text":"3月31日，Adaptive Biotechnologies Corporation（ADPT.US）公布财报，公告显示公司2024财年第一财季净利润为-47.51百万美元，同比增加17.66%；其中营业收入为41.87百万美元，同比增加11.21%，每股基本收益为-0.33美元。从资产负债表来看，Adaptive Biotechnologies Corporation（ADPT.US）总负债3.46亿美元，其中短期债务9.59百万美元，资产负债比为1.80，流动比率为0.05。机构评级：截至2024年3月31日，当前有6家机构对Adaptive Biotechnologies Corporation目标价做出预测，其中目标均价为6.33美元，其中最低目标价为5.00美元，最高目标价为10.00美元。公司简介：Adaptive Biotechnologies Corp 是一家通过利用适应性免疫系统的固有生物学来改变疾病的诊断和治疗，来推进免疫驱动医学领域的公司。 其临床诊断产品 clonoSEQ 经 FDA 授权，用于检测和监测多发性骨髓瘤（“MM”）、B 细胞急性淋巴细胞白血病（“ALL”）和慢性病患者的微小残留病（“MRD”） 淋巴细胞白血病（“CLL”），也可作为 CLIA 验证的实验室开发测试（“LDT”）用于其他淋巴癌患者，包括弥漫性大 B 细胞淋巴瘤（“DLBCL”）。（以上内容为腾讯自选股基于公开消息，由程序或算法智能生成，仅作为用户看盘参考，不作为投资建议或交易依据。股市有风险，请谨慎决策。）","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.25.1","shortVersion":"4.25.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2435359591"}